There has been much recent research into the therapeutic use of stem and progenitor cells for various diseases. Alongside this, there has also been considerable interest in the normal roles that endogenous precursor cells may play in both physiological and pathological settings. In the present review, we focus on two types of progenitor cell which are of potential relevance to vascular homoeostasis, namely the EPC (endothelial progenitor cell) and the smooth muscle progenitor cell. We discuss evidence for their existence and sources in adults, and the various techniques currently used to identify these cells. We examine data obtained from studies using different methods of progenitor identification and relate these to each other, in order to provide a framework in which to interpret the literature in this area. We review evidence for the influence of these vascular progenitor cells upon vascular function and the development and progression of atherosclerosis.
INTRODUCTION
The last decade has seen a huge interest in the field of regenerative biology, with particular emphasis on the use of isolated or purified stem and progenitor cells to try to restore structure and function to damaged organs. Although several different types of cell have been studied, one which has created particular interest is the so-called EPC (endothelial progenitor cell). EPCs are believed to be the postnatal equivalent of angioblasts, i.e. those cells found in embryonic life which form the walls of 'blood islands' that gradually develop into the vasculature. Alongside an understanding of potential therapeutic applications, there has also been increasing appreciation of the physiological roles that these precursor cells might play in the homoeostasis of the adult vasculature. This has altered our paradigms for understanding physiological and pathological processes such as endothelial function and atherosclerosis. In the present review, we will focus predominantly on EPCs, first discussing evidence for their existence in the adult and early studies indicating their relevance, with particular emphasis on the cardiovascular system. We will then deal with the current major limiting issue of definitions for these cells and discuss their potential sources in adult life. Thereafter we will consider the putative role of EPCs in endothelial repair and evidence for their influence on atherosclerosis.
Another circulating progenitor cell population in the adult, which has received less attention than the EPC, is the putative SMPC (smooth muscle progenitor cell). Various studies in animals and humans have suggested that SMPCs may also modulate the formation of atheroma and hence they will also be discussed in the present review.
IDENTIFICATION AND INITIAL WORK ON EPCs
Concepts of stem and progenitor properties are crucial to the subsequent discussion. Stem and progenitor cells share two fundamental properties which distinguish them from more mature and differentiated cells, namely a marked self-replicative ability and the capacity to differentiate to produce functional progeny (of one or more lineage type) [1, 2] . The distinction between 'stem' and 'progenitor' cells is somewhat blurred, with progenitors being further along the spectrum of maturation and hence displaying a more restricted proliferative potential and number of lineages along which they may proceed. In reality, there is likely to be a continuous spectrum of cell types, from stem to fully differentiated. For a population of cells at the same stage (rather than an individual cell) one can make broad predictions about their proliferative and differentiating characteristics. Hence when the term 'progenitor' is used within the constraints of current definitions (as discussed below), it is important to recognize that this will encompass cells at different stages of commitment and maturation.
Putative circulating endothelial progenitors were first described in the adult human by Asahara et al. [3] in Boston in 1997. They used the presence of CD34 to sort cells from the adult peripheral blood mononuclear component, based on the knowledge that this antigen is carried by both the angioblasts and haemopoietic stem cells responsible for vasculogenesis in embryonic life. By culturing MNCs (mononuclear cells) enriched or depleted in these CD34
+ cells, they demonstrated that the CD34 + component is able to give rise to spindleshaped cells after 3 days, which become attached to fibronectin. Such culture led to an up-regulation of endothelial lineage markers such as CD31, Flk-1 and Tie2, and loss of the pan-leucocyte CD45 antigen, in these attaching cells. Additional analyses of these attaching cells at 7 days demonstrated binding of lectin (Ulex europaeus agglutinin-1) and uptake of acetylated LDL (low-density lipoprotein), both of which are hallmarks of the endothelial lineage, although these features have also been described in haematopoietic cells and hence are not specific for endothelium [4] . Asahara et al. [3] went on to deliver labelled, CD34
+ -enriched, MNCs into mouse and rabbit models of hindlimb ischaemia and demonstrated neovascularization in the relevant limb with apparent incorporation of labelled cells into capillary walls. In separate experiments, they delivered murine labelled-MNCs enriched for Flk-1 and similarly found incorporation into capillaries and small arteries in the mouse hindlimb ischaemia model. Carriage of CD31 and lectin binding was seen in these incorporated cells [3] . This demonstration that there were circulating cells in adult blood which could differentiate into cells of endothelial lineage and enhance revascularization through vasculogenesis was a landmark finding. The same group of investigators went on to perform bone marrow transplantation work in transgenic mice [5] . Through this, they were able to demonstrate a bone marrow origin of the EPCs which became incorporated into capillaries in both physiological situations (corpus luteum and endometrial growth) and pathological states (hindlimb ischaemia and myocardial infarction). The actual incorporation of cells into host vasculature is a critical part of the EPC definition, since augmentation of neovascularization may take place via a number of other mechanisms, such as production of paracrine factors or cell-cell contact-mediated signalling.
ISSUES OF DEFINITION FOR EPCs
Since these key publications, an enormous amount of research has been undertaken into EPCs; however, in attempting to collate and interpret these results, a major limiting factor is that the 'EPCs' studied by one group are not necessarily the same cell type as those of another. This pertains to the unresolved issue of how EPCs should best be defined. As implied above, two main methods of classification have been utilized.
Antigen-based definitions
The first method of classification is based on expression of cell-surface antigens, typically using flow cytometry to quantify relevant populations. ECs (endothelial cells) display a characteristic combination of such antigens, including CD34, KDR {kinase insert domain-containing receptor; a type of VEGFR2 [VEGF (vascular endothelial growth factor) receptor 2]}, VE-cadherin, vWF (von Willebrand factor) and E-selectin. However, it is acknowledged that there is a qualitative and quantitative heterogeneity of antigen expression on ECs, with patterns varying between different vessels and organs, and also depending on the state of activation of the endothelium [6, 7] . For example, in a previous study it was seen that lung alveolar capillary endothelium and renal glomerular fenestrated endothelium had strong expression of CD34, while endothelium from sinusoids of the spleen was negative for CD34, whereas in hepatic sinusoids CD34 expression was restricted to periportal areas [7] .
It is recognized that mature ECs may be present in the circulation, albeit at low levels, as the result of shedding from vessel walls and that these levels are increased after vascular injury [8] . In order to distinguish such cells from circulating endothelial progenitors (which are also present at very low levels), some groups have additionally used other antigens which are lost during maturation of endothelial lineage cells, most commonly CD133 (also termed AC133) [9] . Hence the use of a carefully chosen group of markers should select for immature, rather than mature, endothelial lineage cells; the combination of CD34, KDR and CD133 has been used by several investigators, although many others have used only two of these three. Unfortunately, even with use of all three, this phenotype is not entirely specific, this same cluster of antigens may also be found on haemopoietic stem cells [10, 11] . This relates to the probable origin of haemopoietic and EC lines from a common precursor, termed the haemangioblast. As haemopoietic stem cells differentiate, CD34, KDR and CD133 antigens are down-regulated and disappear. Hence a limitation of the antigenic method of defining EPCs is that it will certainly include early haemopoietic lineage cells, as well as committed endothelial lineage cells at several stages of differentiation from early 'angioblast' (i.e. immature but lineage-committed) onwards. Furthermore, the use of a greater number of markers is a double-edged sword; for example, use of CD133 to ensure the distinction from mature ECs will also lead to the exclusion of 'later' or 'more mature' EPCs which may have lost this marker, while not yet being terminally differentiated. The probabilistic nature of antigenic carriage for cell populations at any given maturation point makes this problem inherent to antigen-based definitions. Additionally, using combinations of a greater number of markers makes the number of cells thereby identified even fewer, further impairing the reliability associated with 'rareevent' detection by flow cytometry [12] . To complicate matters further, while the use of antigenic combinations may have logical appeal, whether this approach actually identifies a group of precursors capable of producing ECs has recently been challenged (as described below) [13] .
Culture-based definitions
The second commonly employed definition for EPCs derives from in vitro culture work. The original paper by Asahara et al. [3] described in vitro culture (on fibronectin) of CD34-enriched MNCs leading to the formation of spindle-shaped attaching cells within 3 days. Co-culture of CD34-enriched and CD34-depleted cells gave rise, within 12 h, to multiple clusters, containing round cells centrally and sprouts of spindle-shaped cells at the periphery. The latter took up acetylated LDL, whereas the former did not. This cluster appearance was reminiscent of the blood islands previously described, wherein angioblasts surround haemopoeitic stem cells as the initial stage of vasculogenesis [14] . Since then, various culture preparations have been used to encourage endothelial lineage proliferation from human bloodderived MNCs. There has been a considerable variation in the details of techniques used: for example, some have replated the adherent cells after 2 days initial culture, whereas others have used the non-adherent cells at this time [15, 16] . Nevertheless, different groups have provided a number of (perhaps surprisingly) consistent findings: there appear to be (at least) two distinct types of cell which develop after culture in vitro in endothelial growth medium, as discussed below.
EARLY EPCs AND OECs (OUTGROWTH ECs)
The first type of EPCs appear after 3-5 days of culture, are spindle-shaped, have peak growth at approx. 2 weeks and die by 4 weeks. These have been variously termed 'early EPCs' by Gulati et al. [17] and Hur et al. [18] , 'attaching cells' by Asahara et al. [3] and CACs (circulating angiogenic cells) by Rehman et al. [19] . The second type of EPCs appears only after longer culture, of approx. 2-3 weeks, forming a cobblestone monolayer with near-complete confluence, and can show exponential population growth without senescence over 4-8 weeks and live for up to 12 weeks. These were termed 'late EPCs' by Hur et al. [18] or OECs by Lin et al. [20] and Gulati et al. [17] . These two cell types appear to differ from each other in several respects (see Table 1 ). For clarity, we will use the terms early EPCs and OECs in the present review.
OECs have many similarities to mature ECs, in terms of antigen carriage (including vWF, VE-cadherin and KDR) and high levels of NO production, by eNOS [endothelial NOS (NO synthase)] [17, 18, 20] . They are able to participate effectively in tube-forming assays in vitro. However, OECs differ from mature ECs in having far greater proliferative ability in vitro and greater angiogenic potential in vivo. Ingram et al. [21] used a novel single-cell replating technique to assess clonogenicity and proliferative potential of individual OEC-type cells from adult humans. They found a hierarchy of proliferative potential among OECs with a pyramidal distribution (although whether such a hierarchy actually exists among circulating cells in vivo is unknown). A small population of OECs with the highest proliferative potential was able to produce more than 200 progeny per replated cell. Collectively, these features make OECs (and the circulating cells from which OECs are derived) attractive candidates for therapeutic use in neovascularization (see below); however, the prolonged culture conditions required for OEC generation renders their contribution to endogenous vascular repair uncertain [22] . (This highlights a salient point relating to all culture-based definitions, namely that the intervention imposed on the cells has effects on phenotype and function, hindering extrapolation from in vitro to in vivo situations). Early EPCs, in contrast, do not participate in tubeforming assays, have only weak invasive ability on gels and produce only low levels of NO [18] . They do, however, demonstrate some features in keeping with (although not specific for) an endothelial lineage such as acetylated LDL uptake and lectin binding. Importantly, early EPCs do not develop into OECs upon prolonged culture. Among antigenic markers, CD14 (a monocytic marker) has been found by several groups on early EPCs [17, 23, 24] . Other antigens variably found on early EPCs are suggestive of an endothelial-type fate (e.g. Tie2 and Flk-1) and yet haemopoietic origins (e.g. the pan-leucocyte marker CD45) [25] . Early EPCs lack the impressive replicative ability of OECs, but are prolific producers of several growth factors, cytokines and chemokines, including VEGF, IL (interleukin)-8, HGF (hepatocyte growth factor), G-CSF (granulocyte colony-stimulating factor) and GM-CSF (granulocyte/macrophage colony-stimulating factor) [19] . Work by Hur et al. [18] indicated that early EPCs and OECs actually had comparable ability to augment angiogenesis when delivered into an in vivo animal model of ischaemia [18] . This group went on to demonstrate an additive effect when using the two cell types together in this model, and speculated that the paracrine effects of cytokines produced by early EPCs may enhance the more direct incorporation of OECs into new or growing vessels [25] . (In fact, it seems likely that a dichotomy of early EPCs as 'software' modulating the function of OECs as 'hardware' is oversimplistic since, in at least two animals models, delivered OECs are able to enhance re-endothelialization without their long-term incorporation [26, 27] ).
The lineage origin of these two culture-derived endothelial-type cells has been examined. Expression of the pan-leucocyte antigen CD45 is relatively greatest in MNCs, lower in early EPCs and lowest in OECs [18] . It appears that early EPCs are mostly derived from a CD14 + population of MNCs, implying a monocytic, rather than true endothelial, lineage (despite the endothelialtype features described above) [25] . Other monocytic markers (Mac-1 and CD11c) have also been identified on early EPCs [19] . In contrast, OECs derive exclusively, or almost exclusively, from the (numerically far smaller) CD14
− population of MNCs [17, 25] . It has been suggested that the MNCs from which OECs are derived may represent a 'true' circulating endothelial precursor (angioblast) [22] . Somewhat against this suggestion is the observation that transplantation of cells obtained after 4 days culture from either CD14 + or CD14 − MNC fractions improves neovascularization in vivo, whereas transplantation of freshly isolated CD14 + or CD14 − MNCs does not [24] ; however, this may of course simply reflect the very low number of 'true angioblasts' among circulating MNCs.
CFUs (COLONY FORMING UNITS)
Methods of quantification of endothelial progenitors using culture techniques have also been developed, by extension from the original descriptions of 'cell clusters' by Asahara et al. [3] . Hill et al. [15] developed a colonyforming assay based on culture of MNCs on fibronectincoated plates, using culture medium designed to promote endothelial lineage cell proliferation. After 2 days, non-adherent cells were collected and replated for a further 5 days. They identified colonies (termed CFUs) composed of multiple thin flat cells emanating from a central cluster of rounded cells ( Figure 1 ). Colony counts were used as an indicator of the number of circulating progenitors and the spindle-shaped cells at the periphery of the colonies were themselves termed 'EPCs'. Hill et al. [15] demonstrated intra-subject and inter-observer reproducibility of this colony-counting assay and others have subsequently used this assay to document changes in relation to specific interventions. The relevant cell types in this type of CFU have recently been determined. Rohde et al. [28] used subtractive analyses to demonstrate that CFUs are comprised predominantly from T-cells and monocytes, with some B-lymphocytes and NK (natural killer) cells also detected. Depletion of either T-cell or monocytes prevented colony formation. Purified T-cells and monocytes in combination were able to form CFUs. Of note, CFUs could form in the absence of CD34 cells. Hur et al. [29] characterized a population of T-cells, bearing the antigens CD3, CD31 and CXCR4 (CXC chemokine receptor 4), which were necessary for colony formation and which are found at the centre of CFUs. They demonstrated copious production of angiogenic cytokines and found that these cells were able to enhance various in vitro and in vivo assays of vessel formation.
These recent findings suggest that it is inappropriate to continue referring to this type of CFUs as 'EPC colonies' or 'CFU-EC'. Nevertheless, this CFU continues to be relevant to those investigating cardiovascular disease since CFU numbers have been found to correlate with a variety of clinically relevant indices, including endothelial function (derived from brachial artery reactivity) and cardiovascular events [15, 30] . This indicates that CFU levels can serve, at the very least, as a marker of underlying processes associated with major clinical end points. Moreover, the fact that cells in CFUs can influence vascular remodelling suggests that more detailed characterization of these cells' physiological and pathological roles may lead to novel treatments for vascular disease.
Correlation between antigen-and culture-based definitions
Having considered the two alternative strategies for identifying EPCs, it is of interest to see how they relate to each other. George et al. [31] examined the relationship within individual subjects between EPCs as defined from colony (CFU) formation and EPCs defined on specific antigen carriage. They found that CFU numbers did not correlate with numbers of CD34/KDR double-positive cells or CD34/KDR/CD133 triple-positive cells. A negative correlation was found between CFU numbers and CD34/CD133 double-positive cells. The implication is that different definition approaches are identifying different cells and the results presented above, on the constituent cells of CFUs, support this notion.
More recently, the situation has been explored further by Case et al. [13] . They used peripheral blood MNCs from healthy subjects who had undergone G-CSF administration, and used immunomagnetic selection and FACS to isolate CD34/VEGFR2/CD133 triple-positive cells [13] . These cells were then assayed using two different endothelial culture systems and a haemopoietic colony assay. No endothelial colony formation was found (in either endothelial assay), whereas they found a consistent production of haemopoietic progenitors in appropriate medium. Furthermore the isolated triplepositive cells failed to form capillary-like structures in a Matrigel assay and were universally found to express the haemopoietic marker CD45. Case et al. [13] concluded that CD34/VEGFR2/CD133 triple-positive cells are in fact primitive haemopoietic-lineage-restricted progenitors rather than endothelial progenitors. Their implication is that any enhancement of vascular repair related to these cells must occur through means other than by differentiation to ECs; however, several caveats should be borne in mind with this work, as highlighted by Fadini et al. [12] . First, the use of mobilized peripheral blood means that the distribution of cell lineages cannot be taken as representative of normal peripheral blood and may favour detection by culture of haematopoetic cells over ECs. Secondly, culture of sorted cells may remove critical signals from other cellular sources, which might have otherwise directed cells along a particular (i.e. endothelial) phenotype. Finally, there are also issues regarding the indirect staining employed for KDR, which may have had an impact on appropriate cell isolation.
SOURCES OF EPCs Bone marrow
As discussed above, it was the contention of Asahara et al. [5] that the EPCs which they described originated in bone marrow, shown from their two models of bone marrow transplantation into immunodeficient mice. The bone marrow cells used constitutively expressed β-galactosidase (LacZ), transcriptionally regulated by an endothelial specific promoter (either Flk-1 or Tie2). They then identified Flk-1/LacZ or Tie2/LacZ fusion (RNA) transcripts in tissues of interest using RT (reverse transcriptase)-PCR. Tissues examined included a tumour implantation model (subcutaneously injected mouse syngeneic colon cancer cells) and a woundhealing model (punch biopsy to flank skin) in addition to those described above. Tissue sections were also incubated with X-Gal (5-bromo-4-chloroindol-3-yl β-d-galactopyranoside) to allow identification of areas containing LacZ-expressing cells. In this way, they identified LacZ-positive cells as being present within the developing neovasculature in all of these models. They interpreted these findings as indicating that vessel growth was occurring not simply through angiogenesis, but also by vasculogenesis, mediated through the action of these 'EPCs'. Further support for the bone marrow origin of these cells was indirectly provided from other groups; for example, Kamihata et al. [32] demonstrated enhanced collateral formation in a myocardial infarction model following administration of bone marrow MNCs. Labelled bone marrow MNCs in this model were found to be incorporated into neocapillaries. Other studies in animal models of ischaemia supported these findings [33] [34] [35] . By examining patients who have undergone sexmismatched bone marrow transplantion, Lin et al. [20] showed OECs to be derived from bone marrow. This is in keeping with work by Reyes and Verfaillie [36] who identified a MAPC [multipotent (adult) progenitor cell] within adult human bone marrow, which was CD133 + and Flk-positive but CD34
− and VE-cadherin-negative [36] . This MAPC could differentiate in vitro (with appropriate cues) to produce large quantities of cells which were phenotypically and functionally like mature ECs; however, MAPCs were also capable of differentiating into other mesodermal and neuroectodermal cell types and hence cannot be thought of as having a committed endothelial lineage. The 'true' circulating angioblast/EPC may be a descendant of such bone marrow MAPCs.
This collective body of work has led to several clinical studies of progenitor cell therapy (in humans), which have utilized bone-marrow-derived cells based on this rationale [37] [38] [39] [40] [41] [42] [43] [44] ; however, there may be other sources of endothelial lineage precursors in the adult, as discussed below.
Blood vessel wall
Ingram et al. [45] applied the single cell culture methods detailed above to examine heterogeneity among HAECs (human aortic ECs) [45] . These cells are generally considered to be terminally differentiated mature ECs; however, it proved possible to passage HAECs for at least 40 population doublings. Furthermore, as a demonstration of clonogenicity, they found that a proportion of singly cultured HAECs were able to form colonies comprising more than 2000 cells. A similar proportion of their clonal progeny were able to yield secondary colonies or confluent layers on replating and further culture. The authors therefore inferred that, within the group of HAECs, there is a subpopulation of HPP-ECFCs (highly proliferative colony-forming endothelial line cells). The variability in the proliferative capacity within the overall group of HAECs suggested a hierarchy of endothelial progenitors within the adult arterial wall, with HPP-ECFCs at the top of this. This may have an important impact on the focus of therapeutic attempts to enhance progenitor activity, many of which have hitherto concentrated on the mobilization of cells from bone marrow. The vessel wall may, however, contain a less-studied, but nonetheless potentially very important, source of progenitors to assist in repair of nearby vascular injury, equivalent to 'resident' progenitor cells described in other compartments.
Adipose tissue
White adipose tissue may provide an additional and unexpected source of endothelial progenitors. The stromalvascular compartment has a heterogeneous composition which appears to include various pluripotent cell types. Previously it has been shown that adipose tissue in humans contains progenitor cells which are able to differentiate, after in vitro culture, into cells bearing CD31 and vWF and which will form tube-like structures containing erythrocytes in an in vivo Matrigel assay [46] . Planat-Benard et al. [46] have also reported the ability of human adipocytes to de-differentiate in culture into immature cells which are then capable of differentiating either back to adipocytes or to an endothelial phenotype in appropriate conditions. This raises the possibility of a common bipotential precursor cell in fat which can develop into either endothelial-type cells and adipocytes. Such precursors appear to be CD45-and CD14-negative and hence do not appear to overlap with the monocyte-lineage-derived precursors which may demonstrate endothelial-like properties (see above).
Liver and intestine
Aicher et al. [47] used a complex parabiosis model to demonstrate a contribution by non-bone-marrowderived cells to neovascularization in a mouse ischaemic hindlimb model [47] . They also employed a rat model of sex-mismatched liver or small intestine transplantation, wherein they subsequently induced hindlimb ischaemia in the recipient. In this manner they were able to show that progenitors from these two organs contributed to hindlimb neovascularization. It remains the subject of debate as to whether these incorporating progenitors are originally derived from the vessel wall in the organ of origin or whether they are tissue-resident progenitor cells of non-vascular origin [48] .
Spleen
Several groups have shown that the spleen is a source of MNCs which can differentiate, in appropriate culture, to give an 'EPC phenotype' and which may favourably modulate endothelial function or vascular remodelling [49] [50] [51] [52] . Given the points raised earlier in the present review regarding the specificity of antigenic markers for ECs and the cells constituting 'endothelial-type CFUs', care must be taken in applying the term EPC. As mentioned earlier, a restrictive use of the term EPC to settings where there is proof of direct vascular incorporation (rather than merely a favourable influence on vascular parameters) would reduce some of the confusion presently encountered in the literature.
Kidney
The renal cortical parenchyma is a source of CD133 + cells. These cells are Pax-2 positive (a renal epithelial progenitor marker), but also display mesenchymal markers [53] . Work on CD133
+ cells derived from human renal carcinoma has shown that these cells are able to differentiate into ECs; when co-tranplanted with renal carcinoma cells into SCID (severe combined immunodeficiency) mice, these CD133 + cells enhanced tumour vessel formation and were found to be directly incorporated into the neovessels [54] . Hence there appears to be a tissueresident population in kidney which is able to act, at least in some settings, as a source of endothelial progenitors.
ENDOGENOUS ACTIONS OF EPCs

Regulation of endothelial function
Since vascular ECs have a finite lifespan, and such cells are shed into the circulation in health and disease states, a system must exist by which these cells are then replaced [8, 55] . It has been conventionally thought that this was (entirely) through the migration and proliferation of mature ECs adjacent to regions of injury, under the influence of paracrine mediators released from the injured segments and/or loss of contact inhibition [56] . However, the discovery of endothelial progenitors within adult peripheral blood presented another possible means of vascular maintenance, namely a reservoir of circulating cells which could home to sites of injury and restore endothelial integrity thus allowing continued normal function. Logically then, if the circulating progenitor pool represents an important source of such cells for 'repair', a reduction in the number of progenitors might be expected to have an impact on endothelial function. As an adjunct to this theory, factors which impair endothelial function and increase cardiovascular risk might be expected to have a negative impact on EPC numbers and/or function. Several studies have demonstrated that this last point does largely hold true and these findings are summarized in Table 2 [16, [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] . Conversely, interventions associated with improved endothelial function have been associated with improved EPC numbers: several members of the statin family (3-hydroxy-3-methylglutaryl-CoA inhibitors) of drugs have been shown to raise EPC levels and improve their function, in addition to enhancing in vivo indices of endothelial function [16, 49, [70] [71] [72] [73] [74] . It is, however, acknowledged that this situation may be more complex than merely cause and effect, since these are only some of the many pleiotropic effects of this class of drugs. Several other drugs are able to modulate measurable EPC parameters: these include PPARγ (peroxisome-proliferatoractivated receptor γ ) agonist thiazolidines, G-CSF and erythropoietin, among others [75] [76] [77] [78] [79] [80] [81] . However, as with statins, an interpretation of their effects on endothelial function is complicated by potential pleiotropic actions with all of these agents. Physical exercise is a non-drug intervention which is able to raise EPC numbers and also improve measurable endothelial function [82] [83] [84] [85] . Once again, this association is suggestive of a mechanistic connection but certainly does not prove causation.
Hill et al. [15] studied men without known cardiovascular disease but varying degrees of estimated cardiovascular risk. They assessed endothelial function in a peripheral conduit vessel, using brachial artery flowmediated vasodilation. EPC numbers were measured using their CFU assay discussed above. First, these workers found that an inverse correlation existed between numbers of CFUs and the overall Framingham risk score of the subjects. Furthermore they found a positive correlation between the number of EPCs and brachial artery reactivity of the subjects, compatible with the hypothesis that an adequate pool of EPCs in the blood may be a key requirement for appropriate endothelial function. Indeed, EPC levels were a better predictor of brachial reactivity than the overall Framingham risk score of subjects; however, the basis of this correlation between EPC levels and measurable endothelial function is not known. Each is strongly connected, for example, to NO function (NO mediates both EPC release from bone marrow [86, 87] and relaxation of vascular smooth muscle), hence the findings of Hill et al. [15] might in fact represent an epiphenomenon rather than a causal relationship.
Supportive evidence for an important contribution by the circulating progenitor pool has been provided by a study of patients with CML (chronic myeloid leukaemia) [55] . These patients had acquired, in adult life, a BCR (breakpoint cluster region)/Abl fusion gene in their bone marrow cells as a result of the chromosomal translocation underlying CML. Using a specific gene probe in one such patient, the presence of the BCR/Abl gene in vascular ECs was confirmed, thereby inferring origin from a haemoangioblastic marrow cell in adulthood. Additionally, in a CML patient who received an allogeneic bone marrow transplant, normal donor-type ECs were later detected (post mortem) in sections of myocardial tissue. Hence it appears that bone-marrow-derived cells play a role in the maintenance of adult vascular endothelium, lending credence to the theory that they influence endothelium-dependent vascular function.
There is also relevant animal-based work in this area of progenitor cells and endothelial function. Gulati et al. [27] used a rabbit model of balloon injury to the carotid arteries. They cultured peripheral blood MNCs in endothelial growth medium for 7-12 days, producing endothelial-phenotype cells carrying CD31 and eNOS, and taking up acetylated LDL. They delivered these culturemodified cells immediately after balloon injury and found that, compared with saline-treated controls, local treatment with these cells led to accelerated re-endothelialization. Carotid rings were studied at 4 weeks after balloon injury, using phenylephrine for pre-contraction and then incremental dosing of acetylcholine to produce relaxation. In animals who had received culture-modified MNCs, both maximal relaxation and EC 25 were markedly improved. This work is clearly somewhat removed from assessing endogenous progenitor actions, due to the period of in vitro cell manipulation involved, but nevertheless demonstrates the ability of blood-derived cells to influence endothelial function. He et al. [88] also used a similar rabbit carotid injury model and demonstrated a restoration of endothelial function through the transplantation of circulating progenitors [88] .
Wassmann et al. [50] studied endothelial function in ApoE (apolipoprotein E)-knockout mice, on a highcholesterol diet, with atherosclerotic plaques and demonstrable endothelial dysfunction of aortic rings ex vivo. They found that the intravenous administration of spleenderived MNCs improved endothelium-dependent vasodilation and that this effect was sustained for at least 45 days after treatment. They concluded that these injected cells had become ECs based on a triad of findings: (i) the localization of these fluorescently labelled donor cells to the endothelial monolayer of the recipient; (ii) the histological appearances of an endothelial phenotype to these cells on 7 μm cryosections examined under microscopy; and (iii) the expression of the endothelial marker CD31 by these cells. Whether the improvement in endothelial function is directly due to increased numbers of new ECs or an indirect effect on pre-existing cells is not clear; however, an increase in vascular NOS activity was documented and is likely to mediate the effect.
Anti-atherosclerotic actions
Atherosclerosis is an inflammatory disease and it is recognized that the earliest stages of this process involve an alteration of endothelial function in the affected arterial regions [89, 90] . This allows adhesion of circulating leucocytes to the vessel wall, followed by translocation into the subendocardial area. The stimuli that lead to this abnormal endothelial function are various (hence the several well-described risk factors for atherosclerosis), but all ultimately cause prolonged injury to the vessel wall. The actions of oxidized LDL in this regard have been described in particular detail, but other mediators (including several inflammatory cytokines, advanced glycation endproducts and mechanical factors such as elevated systemic blood pressure and local shear stresses) all result in arterial damage through oxidative stress. It is the response to this injury which appears to be crucial to the development of, or resistance to, atherosclerosis. Rapid and complete restoration of endothelial integrity and function prevents development and growth of a neointimal lesion; however, inadequate response to injury will instead allow the formation of an atheromatous lesion. The discovery of circulating endothelial progenitors has led to the theory that they are important mediators of this repair arm, and hence that a depletion in these cells (in terms of functional availability) would result in an imbalance between injury and repair, favouring atherosclerosis.
Several separate pieces of evidence indirectly suggest that EPCs may play a vital role in the repair arm. The first block comes from clinical work linking EPCs with (i) atherosclerotic risk factors (as already discussed), (ii) quantifiable atheroma burden and (iii) atherosclerotic end points (in terms of cardiovascular outcomes).
The relationship between EPCs and measurable atheroma burden in humans is not straightforward. Since acute ischaemia itself mobilizes EPCs into the peripheral circulation [91] [92] [93] , many association studies have specifically examined EPCs in stable vascular disease. Here, some studies have indicated a reduction in EPC number in the presence of coronary artery disease [16, [94] [95] [96] , and some have suggested a negative correlation between EPC levels and the number of vascular beds affected (based on ultrasound detection of plaque), maximal degree of vessel stenosis or maximal IMT (intimal-media thickness; derived from intravascular ultrasound) [97] [98] [99] [100] . However, other workers have found higher levels of EPCs correlating with greater maximal vessel stenosis in stable disease [101] . The cause for such divergent results may relate to the problem of inconsistent definitions of EPCs in the literature [102] .
Two key papers in 2005 showed a statistical link between EPCs and cardiovascular outcomes [30, 103] . Schmidt-Lucke et al. [103] looked at a group of 120 individuals, comprising normal subjects and also patients with either stable or unstable coronary artery disease. They found that major cardiovascular events [defined as cardiovascular death, unstable angina, myocardial infarction, PTCA (percutaneous transluminal coronary angioplasty), CABG (coronary artery bypass grafting) or ischaemic stroke] were significantly more frequent in the subgroup with lower numbers of circulating CD34/KDR double-positive cells at baseline. This association persists after accounting for conventional cardiovascular risk factors. Werner et al. [30] also studied CD34/KDR double-positive cell numbers in a cohort of 519 patients diagnosed with coronary artery disease by angiography. After adjustment for confounding variables, higher levels of such cells were associated with a reduced risk (at 12 months follow-up) of death from cardiovascular causes and of occurrence of a first cardiovascular event. The authors also examined outcomes when patients were grouped by baseline levels of CFUs (i.e. a culture-based definition of colony formation). Here too, higher CFU formation was associated with a reduced occurrence of a first major cardiovascular event and reduced revascularization at follow-up. However, as discussed above, recent work on the CFU assay suggests that it is assessing the in vitro activity of cells which may be relevant to vascular function, but which are not actually EPCs themselves [28, 29] .
The second block of evidence for EPCs as mediators of vascular homoeostasis comes from animal work. The models of vessel injury employed have fallen into two broad categories (discussed in detail below).
Transluminal endothelial injury
Griese et al. [26] used a balloon-injury model of rabbit carotid artery. They cultured peripheral blood MNCs in endothelial growth medium and utilized the spindle-type cells obtained from colonies at day 5 post-plating. Retroviral transduction with a LacZ gene was performed in vitro and the cells were then injected into the injured arterial segment. Such vessels demonstrated extensive endoluminal coverage with LacZ-positive cells by day 4 post-procedure, in contrast with those treated with saline control after injury. Co-staining with CD31 confirmed the presence of this antigen in incorporated cells, in keeping with the endothelial phenotype. Importantly the neointimal thickness and neointima/media ratio were significantly reduced in vessels treated with EPC transfer, suggesting that rapid endothelial repair may have limited the formation of post-injury neointima.
Walter et al. [74] and Werner et al. [104] used murine models of balloon-mediated arterial injury and found that treatment with statins led to accelerated reendothelialization of the injured segment and reduced intimal formation in this part, and attributed these effects to the demonstrated increase in circulating EPCs; however, the multiple effects of statins confound interpretation to an extent. In addition to EPC mobilization and function enhancement, statins have effects on mature ECs and SMCs (smooth muscle cells) and the relative contribution of these effects to the outcomes is uncertain.
Animal models of cardiovascular risk factors
Several experimental models exist which allow the study of individual cardiac risk factors (such as diabetes, hypertension and hyperlipidaemia) in relation to atherosclerosis and EPCs [61, 105, 106] . Owing to constraints of space, we will consider only hyperlipidaemic models in the present review. The ApoE −/− mouse, with its propensity to develop hyperlipidaemia and atherosclerosis when fed on a Western-type diet, has been extensively used [107] . Relevant work from an EPC perspective was performed by Rauscher et al. [108] who examined the effects of chronic transfer of bone marrow endothelial progenitors (defined as CD31 + /CD45 − ) from either young ApoE −/− mice without atherosclerosis or older ApoE −/− mice with atherosclerosis [108] . They demonstrated that treatment of ApoE −/− mice with cells from young, but not old, ApoE −/− mice was able to prevent the progression of atherosclerosis in the recipient despite the ongoing hypercholesterolaemia. This implies that some protective property of bone marrow progenitors is lost with aging and that this represents a pivotal step in atherogenesis.
Of particular interest was the ability of therapeutically enhanced repair to modify the effects of ongoing injury in the hyperlipidaemic mouse. In ApoE −/− mice on a Western-type diet, persistent hyperlipidaemia is associated with elevated levels of IL-6 and VEGF. Rauscher et al. [108] found that those mice who received competent bone marrow cells showed a marked and sustained reduction in the levels of these cytokines, in contrast with the far more limited, or even converse, effects seen with marrow cells from older donors. Hence it is tempting to infer that the reparative action of competent bone marrow cells was able to suppress the chronic inflammatory process that results from 'unhealed' arterial injury. A later study by George et al. [109] examined the use of in vitro-cultured OEC-type cells in ApoE-knockout mice. They found greater aortic sinus plaque sizes in mice receiving OECs as opposed to control mice. Furthermore the plaques in OEC-treated animals had larger lipid cores and thinner fibrous caps, an appearance suggestive of 'vulnerability' to plaque instability (in human disease).
A recent study by Zoll et al. [110] utilized immune tolerant [Rag2 −/− (recombination activating gene 2)] ApoE-knockout mice. They delivered EPCs obtained (by culture) from human umbilical cord blood into these mice and studied transverse sections of aortic sinus thereafter. Such EPCs appeared to neither prevent the subsequent development of atherosclerosis in this region in young mice nor to prevent its progression in older mice.
Hence models examining the impact of EPCs on atherosclerosis have yielded seemingly divergent results. Once again, the issue of definitions is likely to underlie this in part. Furthermore, it is not possible to directly compare studies in which cells have been only sorted or selected with other work where cells have been cultured in vitro before use. Hence the impact of EPCs on atherosclerosis remains unclarified and simple paradigms casting EPCs as unambiguous mediators of vascular repair may require revision in the future. Mechanisms by which EPCs might actually exacerbate atherosclerosis also remain uncertain but, in the light of their apparent contribution to tumour angiogenesis [111, 112] , a similar effect on atherosclerotic plaque angiogenesis has been postulated [113] .
SMOOTH MUSCLE PROGENITORS IN THE ADULT
Studies on SMCs in plaques
A defining step in the formation of the atherosclerotic plaque is the appearance of SMCs in the intimal layer. These herald the progression of the lesion beyond the mere 'fatty streak' stage. According to Ross' original paradigm [90] , these SMCs originate in the adjacent medial layer of the artery, from where they have migrated across the internal elastic lamina. This was supported by a number of studies demonstrating smooth muscle proliferation in the medial layer after mechanical injury and in atherosclerosis [114] [115] [116] [117] . However, Sata [118] subsequently highlighted a number of points which appeared incongruous with this concept. First, few investigators have actually identified SMCs migrating across the internal elastic lamina into the subendothelial layer. In contrast, many experimental studies have demonstrated the attachment of MNCs to the dysfunctional endothelial layer of an injured artery. Secondly, other work has shown that neointimal formation is possible even in the absence of medial layer cells (which had been induced to undergo apoptosis through deliberate injury) [119] . Thirdly, it was shown that smooth muscle hyperplasia after rat carotid injury could be abrogated by prior administration of MCP-1 (monocyte chemoattractant protein-1), a cytokine which is involved in the recruitment of circulating blood cells, but which has no effect on differentiated medial SMCs [120] . Fourthly, SMCs in the neointima expressed a number of haemopoietic lineage markers (e.g. FK506-binding protein 12 and interferon-regulatory factor), in contrast with SMCs in the arterial media [121] . These observations led to the alternative hypothesis that SMCs seen in atherosclerotic lesions may not originate from arterial media, but instead derive from a circulating population of smooth muscle progenitors. Kashiwakura et al. [122] cultured MNCs derived from murine bone marrow and identified a population from which cells displaying a combination of smooth muscle antigens could be derived. Experimental work, particularly from the group of Sata and Saiura in Japan [119, 123, 128] , has provided further support for the relevance of SMCs derived from the circulation. Some illustrative examples are described below, together with other related and relevant work.
Transluminal endothelial injury
For transluminal endothelial injury, a model involving donor mouse bone marrow, ubiquitously expressing LacZ, with transplantation into a lethally irradiated wild-type mouse was used [119] . The recipient mouse later underwent wire-injury of the femoral artery, an injury which resembled clinically employed angioplasty and produced acute enlargement of the artery. At 1 week, LacZ-positive cells were seen attaching to the endoluminal surface of the injured segments and, over time, the lumen became narrowed due to the formation of a neointima, predominantly composed of SMCs. The majority of neointimal cells were LacZ-positive. In contrast, no LacZ cells were seen in uninjured femoral arteries of control mice which had also undergone bone marrow transplantation from the same donor type.
Transplant arteriopathy (graft vasculopathy)
It is recognized that cardiac transplants in humans and other species are prone to an accelerated and severe form of coronary artery disease, which is the commonest reason for long-term graft failure in man. This has therefore been used as a model to study cellular involvement in the disease process. Saiura et al. [123] performed heterotropic cardiac transplantation from wild-type mice to ROSA26 mice expressing LacZ. Later (4 weeks), the lumen of epicardial arteries was found to have been narrowed by concentric neointimal hyperplasia. The majority of the neointimal cells were found to be recipient cells expressing LacZ. Immunofluorescence studies indicated that these cells expressed various SMC markers such as MHC (myosin heavy chain) and α-smooth muscle actin. Consistent with these findings, other workers have independently reported that recipient cells are a component of the lesions in graft vasculopathy in aortic transplantation models [124] [125] [126] ; however, as discussed later, the findings of these studies have been challenged on the basis of the degree of microscopic resolution (potentially leading to false-positive co-staining), in addition to the specificity of smooth muscle markers employed [127] .
Sata et al. [128] explored the origin of the neointimal recipient cells that they identified. They transplanted wild-type hearts into wild-type mice whose bone marrow had been reconstituted with marrow from ROSA26 mice. At 4 weeks post-cardiac transplant, they found that most neointimal cells were LacZ-positive, implying an origin from recipient bone marrow. Others have, however, highlighted the fact that their technique for double staining makes identification of individual cells difficult, leading to a degree of uncertainty about their conclusions [129, 130] . Furthermore, conflicting findings have been made in other allograft models: several other groups have confirmed the findings of Sata and co-workers of recipient-origin SMCs in transplant atherosclerosis, but found that only a minority of these were of bone marrow origin [125, 126, 131] . Subsequent work from this last group, this time using venous allografts in hyperlipidaemic mice, has in fact implicated the vascular adventitia as a potentially abundant source of SMPCs which may be important in atherosclerosis (see below) [132] .
Hyperlipidaemic animal models
Sata et al. [128] transplanted bone marrow from mice ubiquitously expressing GFP (green fluorescent protein) into 8-week old ApoE −/− mice [128] . They were able to show an accumulation of GFP-positive cells in the atherosclerotic plaques which developed in the aortae of these mice. Approx. 40 % of the α-smooth muscle actinpositive cells in the plaques were also positive for GFP, suggesting a significant bone-marrow-derived contribution to these lesions; however, the caveat noted above remains pertinent. Furthermore, the use of α-smooth muscle actin as a solo marker for the SMC lineage has been criticized due to poor specificity [133] . Bentzon et al. [134] have reported an inability to replicate these findings of Sata et al. [128] on ApoE-knockout/eGFP (enhanced GFP)-expressing mice. Using high-resolution microscopy with deconvolution techniques, they studied approx. 10 000 SMCs in atherosclerotic plaques from these mice and did not identify any such cells of donor (bone marrow) origin. Bentzon et al. [134] went on to perform transplantation of arterial segments from GFP-unlabelled to GFP-labelled ApoE mice. Using a novel collar technique to induce localized atherosclerosis in the graft, they found no evidence of donor cell contribution to plaque SMCs. These findings are noteworthy since their use of sophisticated microscopy reduces the incidence of false co-localization of cell markers, which may explain the discrepancy with preceding work and the impact on the conclusions drawn from other earlier studies in this area.
Recently, Zoll et al. [110] have studied the effects of transfer of human, in-vitro-culture derived, smooth muscle progenitors (see below) into immune-tolerant ApoE-knockout mice. This resulted in a reduction in aortic sinus plaque area compared with controls and an increase in the relative collagen content. The implication from this finding is that such smooth muscle progenitors may have profibrotic actions and hence encourage a more stable plaque phenotype. There appeared to be a transient incorporation of smooth muscle progenitors (only seen for a few days post-cell delivery), hence effects other than direct cell replacement or incorporation are likely to be most relevant in mediating these beneficial effects on plaque size and composition.
Evidence for circulating smooth muscle progenitors in humans
In addition to the wealth of animal model results, there is now work in humans supporting the existence and putative function of smooth muscle progenitors in humans. Simper et al. [135] cultured adult peripheral blood MNCs on EGM-2 (endothelial growth medium-2) enriched with PDGF-BB (platelet-derived growth factor-BB) and produced so-called SOCs (smooth muscle outgrowth cells) [135] . These SOCs developed a typical 'hill and valley' morphology and were positive for α-smooth muscle-cell-specific actin, MHC and calponin on immunofluorescence and Western blotting. Additional CD34, Flt-1 and Flk-1 positivity raised the possibility of descent from the putative bone marrow haemangioblast. SOCs had a greater proliferative potential in vitro than OECs of similar passage and showed greater adhesion to fibronectin. This study was the first demonstration of a smooth-muscle-type cell derived from adult human blood. More recently, Zoll et al. [110] also described the in vitro culture of isolated MNCs from peripheral blood of patients with coronary artery disease. Using 3 weeks of EGM-2, followed by a further 2 weeks in PDGF-BB-enriched medium, they obtained cells with a typical smooth-muscle type 'hill and valley' morphology. These cells stained positively for α-smooth muscle actin and SMHC (smooth muscle MHC). Interestingly, the absolute numbers of SMHC-positive cells from these cultures were significantly reduced in patients who had presented with acute coronary syndromes compared with those who had only stable angina.
Whether these smooth muscle progenitors represent a distinct population, perhaps sharing a common ancestor cell with EPCs, remains uncertain. An alternative possibility is that of a circulating pool of progenitors which is able to differentiate along a (limited) number of different lineages (e.g. endothelial or smooth muscle) in response to specific signals from soluble cytokines and/or direct cellcell ligand interaction [136, 137] . However, a note of caution is warranted in the interpretation of the data above: smooth muscle differentiation in this setting may reflect a plasticity of phenotype in vitro which may not necessarily be reflective of a similar degree of plasticity in vivo. A study in sex-mismatched human cardiac transplants has demonstrated the presence of SMCs of recipient origin within the transplanted heart [138] . Hence, at least in this setting, it appears that SMCs can also be derived in vivo from a circulating source, whose origin is considered next.
Origin of smooth muscle progenitors
Another study by Caplice et al. [129] involved the autopsy examination of patients who had undergone sex-mismatched bone marrow transplantation. Using fluorescence in situ hybridization, they demonstrated that SMCs derived from donor bone marrow were present in the walls of atherosclerotic coronary arteries. More extensive recruitment was found in diseased compared with non-diseased segments of the arteries. To exclude the possibility of cell fusion between donor bone marrow cells and recipient SMCs (a potential confounding factor), chromosomal multiploidy analysis was performed; this confirmed universal diploid cell status and confirmed a lack of cell fusion in this context. Although, on average, only approx. 10 % of SMCs within the atherosclerotic vessel wall were of donor origin, this may well be a reflection of the relatively short time between bone marrow transplantation and death (between 41 months and 4 years in this cohort) compared with the much longer typical time course of atherosclerosis development and progression [139] . The wider applicability of these findings is of course complicated by the indeterminate contribution of other factors in this particular patient cohort, such as chemo-and radio-therapy treatments.
The study by Caplice et al. [129] nevertheless supports a bone marrow origin for at least some of the plaque SMCs found in humans and, by extension, for circulating smooth muscle progenitors; however, other potential sources of smooth muscle progenitors also exist. Perivascular/adventitial cells have been implicated by the animal work of Shi et al. [140] and more recently of Hu and co-workers [132, 141] , as mentioned above. However, it has speculated that the extent of medial cell injury and subsequent cell death in this model may be important in determining the extent to which adventitial cells are mobilized to the neointima; in this context, interposition venous allografts of the type used by both of these groups may be quite different from primary human atherosclerosis [139] . Furthermore, differences in the behaviour of arterial and venous SMCs have been highlighted and may also hinder extrapolation of results from venous allografts to native arterial disease [142] . Other work (in a murine model) has also indicated the presence, within adult skeletal muscle, of 'resident' populations of progenitors that are replenished from bone marrow and which can differentiate to SMCs after muscle injury [143] . Whether they contribute to the circulating pool of such cells, either in normal life or after specific injury, remains unknown.
As is the case for EPCs, a definitive description of the involvement of smooth muscle progenitors in atherosclerotic plaque development and growth is not yet possible. Much of the work described above suggests that SMCs in plaques may arise from a circulating source which therefore contributes to atherogenesis. However, recent work by Zoll et al. [110] challenges this paradigm and hints at a potentially atheroprotective role for these cells. The caveats already described for EPCs (particularly in regard to extrapolation from in-vitro-modified cells to in vivo cell function) are equally pertinent here.
CONCLUSIONS
There is now considerable evidence for the existence of vascular progenitor cell populations circulating within adult human blood. Their discovery has produced major revisions of previously accepted paradigms for vascular homoeostasis and the development of vascular disease; however, much of the evidence implicating progenitors in these processes is indirect, and thus the extent of their contribution to these remains controversial. Difficulty with precise definitions for these cells is currently the major constraint on both further mechanistic research and therapeutic applications. How can we advance the field, given our present tools and understanding? Further research is clearly needed and a consistency in the use of definitions for EPCs and smooth muscle progenitors would greatly facilitate integration of information from different laboratories. Additionally, a more restrictive use of these terms (as discussed in the present review) would be beneficial since it would allow an important distinction between critical mechanisms in vascular modulation: distinguishing between cells which might actually become incorporated into the vasculature (such as 'true' EPCs) and other cell types (such as those in CFUs) which might exert an important influence on vascular remodelling, but which do not themselves seem to become incorporated into vessels. To differentiate between these two distinct effects with confidence, rigorous application of contemporary high-resolution confocal microscopy techniques are mandatory. In terms of research targets, the development of novel markers or techniques to allow more precise and certain identification of EPCs and smooth muscle progenitors would provide a huge leap forward. This would permit the tracking of such cells and assist in the clarification of their true in vivo contribution to vascular remodelling and atherosclerosis. For now, the results summarized in the present review represent our current knowledge in a complex and evolving field.
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